Teva Pharmaceutical Industries, the world’s largest generic drug maker, based in Israel, unveiled its restructuring plan yesterday, which comes with big cuts to its research and development (R&D) department and staff.
Teva Pharmaceutical Industries, the world’s largest generic drug maker, based in Israel, unveiled its restructuring plan yesterday, which comes with big cuts to its research and development (R&D) department and staff.
President and CEO Kare Schultz said in a letter, “The plan will address a number of key areas, including the closure or divestment of a significant number of R&D facilities, headquarters, and office locations across all geographies.”
The plan is said to lead to 14,000 layoffs beginning in 2018, which accounts for about 25% of Teva’s total workforce. The company plans to begin notifying affected employees over the next 3 months. Schultz said that “all business and regions will be affected.” In addition to the layoffs, Teva plans to suspend its dividend on ordinary shares.
Shares in Teva were up 14.6% on news of the plan, though its shares overall are down 53% since January.
The 2-year restructuring plan aims to cut Teva’s costs by $3 billion by the end of 2019, from an estimated base of $16.1 billion, according to Fierce Biotech. However, the restructuring itself will end up costing the company at least $700 million in 2018, mainly related to severance costs, according to a statement.
“We will execute this plan in a timely and prudent manner, remaining focused on revenue and cash flow generation, in order to make sure Teva is ready to meet all of its financial commitments,” said Schultz in the letter.
Reuters reports that Teva needed to make a change in order to stay afloat, as it was saddled with about $35 billion of debt after acquiring Allergan’s Actavis generic drug business for $40.5 billion.
The company also expects to receive help next year from 2 new branded products — its migraine drug fremanezumab and austedo, which treats abnormal, involuntary movements associated with Huntington’s disease. Teva is also partnered with Celltrion in the development of 2 biosimilars: CT-P10, a proposed rituximab biosimilar, and CT-P6, a proposed trastuzumab biosimilars.
Teva is expected to provide its 2018 outlook in February, and will give a longer-term strategic plan for the company later that year.
FDA and Industry Experts Unpack Biosimilar Device Requirements
October 23rd 2024At the GRx+Biosims 2024 conference, a panel of industry experts and FDA officials discussed evolving device requirements for biosimilars and interchangeable biosimilars, highlighting new approaches to comparative use human factors studies, regulatory challenges, and alternative validation methods.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Eye on Pharma: Aflibercept Legal Drama; PBM, Humira Biosimilars; Denosumab Regulatory Review
October 15th 2024Regeneron appeals legal decision after judge refuses to block an aflibercept biosimilar; Prime Therapeutics, a pharmacy benefit manager (PBM), becomes the latest to offer biosimilars referencing Humira (adalimumab) at a low cost; the FDA and European Medicines Agency accept a denosumab biosimilar candidate for review.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Sandoz Report: A Unified Approach to Overcoming Drug Shortages
October 10th 2024A report from Sandoz emphasizes the need for collaboration among stakeholders to eliminate drug shortages impacting over 90% of hospital systems in the US, recommending policy changes and actions to address the ongoing issue, which has caused treatment delays and increased costs.